SEC Form 4 · accession 0001562180-18-003787
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert V Baumgartner
Director
Period of report
Aug 24, 2018
Accepted (ET)
Aug 28, 2018 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 24, 2018 | M | 5,000 | $61.46 | A | 12,712 | D | |
| Common StockF1 | Aug 24, 2018 | S | 5,000 | $188.4667 | D | 7,712 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy) | $61.46 | Aug 24, 2018 | M | 5,000 | D | Oct 28, 2010 | Oct 27, 2020 | Common Stock | 5,000 | 0 | D |
| Stock Option (right to buy) | $91.78 | holding | — | — | — | Oct 30, 2014 | Oct 30, 2024 | Common Stock | 4,000 | 4,000 | D |
| Stock Option (right to buy) | $87.39 | holding | — | — | — | Oct 31, 2013 | Oct 30, 2023 | Common Stock | 4,000 | 4,000 | D |
| Stock Option (right to buy) | $87.34 | holding | — | — | — | Oct 29, 2016 | Oct 28, 2025 | Common Stock | 4,260 | 4,260 | D |
| Stock Option (right to buy) | $70.35 | holding | — | — | — | Oct 27, 2011 | Oct 26, 2021 | Common Stock | 5,000 | 5,000 | D |
| Stock Option (right to buy) | $66.90 | holding | — | — | — | Oct 25, 2012 | Oct 24, 2022 | Common Stock | 5,000 | 5,000 | D |
| Stock Options (Right to buy)F2 | $125.05 | holding | — | — | — | — | Oct 26, 2027 | Common Stock | 3,125 | 3,125 | D |
| Stock Options (Right to buy) | $101.19 | holding | — | — | — | Oct 26, 2017 | Oct 26, 2026 | Common Stock | 3,985 | 3,985 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.17 to $188.73, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The option vests on the earlier of the one year anniversary of the grant date (10/26/2017) or the date of Bio-Techne 2018 annual meeting of shareholders.